Brief: Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus On Maximizing Trudhesa® Commercial Opportunity

IPI Legacy Liquidation Co

22/02/2023 22:46

Feb 22 (Reuters) - Impel Pharmaceuticals Inc  IMPL.O :
    * IMPEL PHARMACEUTICALS ANNOUNCES STRATEGIC REPRIORTIZATION,
CONTINUES FOCUS ON MAXIMIZING TRUDHESA® COMMERCIAL OPPORTUNITY
    * IMPEL PHARMACEUTICALS INC - COST-SAVING MEASURES ELIMINATE
PIPELINE PROGRAMS AND REDUCE HEADCOUNT BY 16 PERCENT
    * IMPEL PHARMACEUTICALS INC - WILL CONTINUE TO DRIVE
TRUDHESA
GROWTH VIA 90 FIELD-BASED SALES REPRESENTATIVES AND OTHER
COMMERCIAL EFFORTS
    * IMPEL PHARMACEUTICALS - TRUDHESA GROWTH MOMENTUM
CONTINUES, WITH
58 PERCENT INCREASE IN NEW PRESCRIPTIONS FROM Q2 2022 TO Q4 2022
    * IMPEL PHARMACEUTICALS INC - WILL IMPLEMENT AN OPERATIONAL
STREAMLINING PLAN
    * IMPEL PHARMACEUTICALS-PLAN WILL INCLUDE REDUCTION OF
EMPLOYEE,NON-EMPLOYEE EXPENSES,LARGELY IMPACTING RESEARCH,
DEVELOPMENT FUNCTIONS OF ORGANIZATION
    * IMPEL PHARMACEUTICALS INC - PLANS TO REPRIORITIZE SPEND TO
CAPITALIZE ON CONTINUED POSITIVE MOMENTUM IN PAYOR AND
PRESCRIBER UPTAKE OF TRUDHESA
    * IMPEL PHARMACEUTICALS INC - FOLLOWING THESE AND OTHER
STRATEGIC
MEASURES, PROJECTS IT WILL HAVE SUFFICIENT CAPITAL TO FUND
OPERATIONS INTO Q3 2023
    * IMPEL PHARMACEUTICALS - PLAN WILL HALT RESEARCH,
DEVELOPMENT
EFFORTS ON INP105 TO ADDRESS ACUTE AGITATION, AGGRESSION IN
AUTISM SPECTRUM DISORDER

Source text for Eikon:  ID:nGNX4RGVKd 
Further company coverage:  IMPL.O 
 ((Reuters.Briefs@thomsonreuters.com;;))